Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.43 |
| ▸ | PREP | P48147 | 7/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034737 | 1.00 | DPP4 (0.43) | DPP4PREPGRIA2DPP8DPP9 | |
| SCHEMBL14190191 | 1.00 | DPP4 (0.43) | DPP4PREPGRIA2DPP8DPP9 | |
| SCHEMBL5034848 | 0.89 | HSD11B1 (0.41) | GRM5 | |
| SCHEMBL5032578 | 0.87 | HCRTR1 (0.39) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14190189 | 0.87 | HCRTR1 (0.39) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5032582 | 0.87 | HCRTR1 (0.39) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5035256 | 0.85 | KMT2A (0.41) | GRM5 | |
| SCHEMBL5034894 | 0.84 | RAB9A (0.40) | — | |
| SCHEMBL5036600 | 0.81 | HPGD (0.43) | — | |
| SCHEMBL5035234 | 0.80 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | claimed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | claimed |
| US-7371751-B2 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1694673-B1 | THIAZOLE DERIVATES | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | EP | disclosed |
| EP-1694673-A1 | NOVEL THIAZOLE DERIVATES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| US-20050153962-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153962-A1 | Thiazole derivatives | CNR1, CNR2, GPR119 | DPP4 973/4885PREP 3229/4885GRIA2 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.